|Bid||105.30 x 300|
|Ask||105.40 x 100|
|Day's range||104.30 - 106.50|
|52-week range||28.35 - 136.90|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||133.33|
Puma Biotechnology, Inc. , a biopharmaceutical company, announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma’s drug neratinib in patients with early stage HER2-positive breast cancer in the journal The Lancet Oncology.
Puma crashed after sales of its breast cancer drug crushed views but failed to live up to more bullish expectations.
The Los Angeles-based company said it had a loss of $2.07 per share. Losses, adjusted for stock option expense, were $1.36 per share. The results exceeded Wall Street expectations. The average estimate ...
Shares of Puma Biotechnology Inc. fell more than 8% late Thursday after the biotech company reported an adjusted third-quarter loss in line with expectations, and sales that were above Wall Street forecasts. ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the third quarter and nine months ended September 30, 2017. Unless otherwise stated, all comparisons are for the third quarter and nine months of 2017 compared to the third quarter and nine months of 2016.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company, including recent developments, at 11:00 a.m.
Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.
Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.
Puma Biotechnology, Inc. , a biopharmaceutical company, has entered into a loan agreement with Silicon Valley Bank, the bank of the world’s most innovative companies and their investors, and Oxford Finance, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, for a term loan of up to $100 million, subject to funding in two tranches.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company, including recent developments, at 11:30 a.m.
Puma Biotechnology, Inc. , a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 9, 2017, following release of its third quarter 2017 financial results.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma's drug neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) in a proffered paper oral session at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. Neratinib was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX™ (neratinib) tablets.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, which will be held September 8 – 12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: www.esmo.org. Abstract #1490: Neratinib after trastuzumab-based adjuvant therapy in early stage HER2-positive breast cancer: 5-year analysis of the Phase III ExteNET trial.
Jim Cramer puts the market into perspective and reveals the high-flying tech company that was cheaper than many investors had thought.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has issued its Day-180 List of Outstanding Issues in the process of their ongoing regulatory review of Puma’s Marketing Authorisation Application (MAA) for neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer in patients who have previously been treated with trastuzumab (Herceptin®)-based adjuvant therapy. The CHMP has requested additional data analyses related to the safety and efficacy of neratinib and has instituted a clock stop in order to allow Puma time to respond to this List of Outstanding Issues.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that based on its recent meeting with the Rapporteur, Co-Rapporteur and review team members, as well as the European Medicines Agency (EMA), the Company plans to modify the summary of product characteristics (SmPC), sometimes referred to as the European product label, in its Marketing Authorisation Application (MAA) to restrict the intended population to patients initiating neratinib treatment within one year after completion of adjuvant trastuzumab therapy. The proposed SmPC will continue to include both hormone receptor positive and hormone receptor negative patients. Puma recently conducted a meeting with the Rapporteur, Co-rapporteur and members of the review team as well as EMA to discuss the responses to the 120-day list of questions received in connection with the Company’s MAA for neratinib that was submitted in the summer of 2016.